Revolutionising Healthcare with Artificial Intelligence
Unlocking the genome and harnessing AI for precision diagnosis of antimicrobial resistance (AMR)About Us
Powered by artificial intelligence and machine learning, AarogyaAI®’s products rapidly and comprehensively diagnose drug resistance, enabling clinicians to make data-driven treatment decisions.Learn More
AarogyaAI®’s products are pathogen and sequencing hardware agnostic. They can be accessed across devices including desktops, mobiles, and tablets, from anywhere.Learn More
Built and trained on global and local databases as well as extensive literature research, AarogyaAI®’s algorithms detect antimicrobial resistance and search for novel mutations contributing to drug resistanceLearn More
AarogyaAI® showcased its product at significant international and national conferences, like the Centre-State Science Conclave and the Union World Conference on Lung Health.
AarogyaAI®'s R&D, operations and analytics teams expand.
AarogyaAI® raises $700,000 seed funding from Info Edge (India)-backed Redstart Labs and Avaana Capital as well as existing investors Entrepreneur First (EF) and First In Ventures.
Ilumina for start-ups invests in AarogyaAI®’s mission through technical support, genomic sequencing, mentorship and peer learning. First In Ventures, USA was also an investor.
AarogyaAI® raises pre-seed funding of $55,000 from Entrepreneur First, UK.
As a health tech start-up, AarogyaAI® joins the fight against Anti Microbial Resistance (AMR), a growing global threat.
Sign up here for latest updates from us